February 3, 2022 01:58 PM EST
R&D

'We need to do more': Mer­ck CEO Rob Davis high­lights M&A, deals strat­e­gy ahead of '28 Keytru­da patent cliff

Nicole DeFeudis

Editor

With megablock­buster Keytru­da’s patent cliff loom­ing in 2028, Mer­ck has made some bold M&A moves in an at­tempt to find its next big mon­ey­mak­er, in­clud­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times